The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: A systematic review

Edward Vincent Loftus, Jr, P. Schoenfeld, W. J. Sandborn

Research output: Contribution to journalReview article

354 Citations (Scopus)

Abstract

Aim: To quantify, through systematic review, the epidemiology and natural history of Crohn's disease in North America. Methods: The selected articles contained: (i) population-based samples of patients followed from the time of diagnosis; and (ii) objective diagnostic criteria for disease. Studies on the natural history of Crohn's disease also contained sufficient follow-up. Data collection and analgsis: For prevalence studies, data on the incidence, prevalence, gender and age at diagnosis were extracted. For natural history studies. data on the disease activity, use of medications and surgery were extracted. Main results: The prevalence of Crohn's disease in North America ranges from 26.0 to 198.5 cases per 100 000 persons. The incidence rates range from 3.1 to 14.6 cases per 100 000 person-years. Most patients have a chronic intermittent disease course, while 13% have an unremitting disease course and 10% have a prolonged remission. Less than half require corticosteroids at any point. During any given year, approximately 10% are treated with corticosteroids and 30% are treated with 5-aminosalicylates. Up to 57% of patients require at least one surgical resection. Conclusions: Between 400 000 and 600 000 patients in North America have Crohn's disease, and the natural history is marked by frequent exacerbations requiring treatment with corticosteroids. 5-aminosalicylate products and surgery.

Original languageEnglish (US)
Pages (from-to)51-60
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume16
Issue number1
DOIs
StatePublished - 2002

Fingerprint

North America
Crohn Disease
Epidemiology
Mesalamine
Adrenal Cortex Hormones
Natural History
Population
Incidence
Chronic Disease
Cross-Sectional Studies
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America : A systematic review. / Loftus, Jr, Edward Vincent; Schoenfeld, P.; Sandborn, W. J.

In: Alimentary Pharmacology and Therapeutics, Vol. 16, No. 1, 2002, p. 51-60.

Research output: Contribution to journalReview article

@article{ab74f70393594c9a83e3cb78ddf71bfa,
title = "The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: A systematic review",
abstract = "Aim: To quantify, through systematic review, the epidemiology and natural history of Crohn's disease in North America. Methods: The selected articles contained: (i) population-based samples of patients followed from the time of diagnosis; and (ii) objective diagnostic criteria for disease. Studies on the natural history of Crohn's disease also contained sufficient follow-up. Data collection and analgsis: For prevalence studies, data on the incidence, prevalence, gender and age at diagnosis were extracted. For natural history studies. data on the disease activity, use of medications and surgery were extracted. Main results: The prevalence of Crohn's disease in North America ranges from 26.0 to 198.5 cases per 100 000 persons. The incidence rates range from 3.1 to 14.6 cases per 100 000 person-years. Most patients have a chronic intermittent disease course, while 13{\%} have an unremitting disease course and 10{\%} have a prolonged remission. Less than half require corticosteroids at any point. During any given year, approximately 10{\%} are treated with corticosteroids and 30{\%} are treated with 5-aminosalicylates. Up to 57{\%} of patients require at least one surgical resection. Conclusions: Between 400 000 and 600 000 patients in North America have Crohn's disease, and the natural history is marked by frequent exacerbations requiring treatment with corticosteroids. 5-aminosalicylate products and surgery.",
author = "{Loftus, Jr}, {Edward Vincent} and P. Schoenfeld and Sandborn, {W. J.}",
year = "2002",
doi = "10.1046/j.1365-2036.2002.01140.x",
language = "English (US)",
volume = "16",
pages = "51--60",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America

T2 - A systematic review

AU - Loftus, Jr, Edward Vincent

AU - Schoenfeld, P.

AU - Sandborn, W. J.

PY - 2002

Y1 - 2002

N2 - Aim: To quantify, through systematic review, the epidemiology and natural history of Crohn's disease in North America. Methods: The selected articles contained: (i) population-based samples of patients followed from the time of diagnosis; and (ii) objective diagnostic criteria for disease. Studies on the natural history of Crohn's disease also contained sufficient follow-up. Data collection and analgsis: For prevalence studies, data on the incidence, prevalence, gender and age at diagnosis were extracted. For natural history studies. data on the disease activity, use of medications and surgery were extracted. Main results: The prevalence of Crohn's disease in North America ranges from 26.0 to 198.5 cases per 100 000 persons. The incidence rates range from 3.1 to 14.6 cases per 100 000 person-years. Most patients have a chronic intermittent disease course, while 13% have an unremitting disease course and 10% have a prolonged remission. Less than half require corticosteroids at any point. During any given year, approximately 10% are treated with corticosteroids and 30% are treated with 5-aminosalicylates. Up to 57% of patients require at least one surgical resection. Conclusions: Between 400 000 and 600 000 patients in North America have Crohn's disease, and the natural history is marked by frequent exacerbations requiring treatment with corticosteroids. 5-aminosalicylate products and surgery.

AB - Aim: To quantify, through systematic review, the epidemiology and natural history of Crohn's disease in North America. Methods: The selected articles contained: (i) population-based samples of patients followed from the time of diagnosis; and (ii) objective diagnostic criteria for disease. Studies on the natural history of Crohn's disease also contained sufficient follow-up. Data collection and analgsis: For prevalence studies, data on the incidence, prevalence, gender and age at diagnosis were extracted. For natural history studies. data on the disease activity, use of medications and surgery were extracted. Main results: The prevalence of Crohn's disease in North America ranges from 26.0 to 198.5 cases per 100 000 persons. The incidence rates range from 3.1 to 14.6 cases per 100 000 person-years. Most patients have a chronic intermittent disease course, while 13% have an unremitting disease course and 10% have a prolonged remission. Less than half require corticosteroids at any point. During any given year, approximately 10% are treated with corticosteroids and 30% are treated with 5-aminosalicylates. Up to 57% of patients require at least one surgical resection. Conclusions: Between 400 000 and 600 000 patients in North America have Crohn's disease, and the natural history is marked by frequent exacerbations requiring treatment with corticosteroids. 5-aminosalicylate products and surgery.

UR - http://www.scopus.com/inward/record.url?scp=0036161786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036161786&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2002.01140.x

DO - 10.1046/j.1365-2036.2002.01140.x

M3 - Review article

C2 - 11856078

AN - SCOPUS:0036161786

VL - 16

SP - 51

EP - 60

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 1

ER -